Литература. 
Липопротеин-ассоциированная фосфолипаза А 2: роль в развитии мозговых инсультов

1. Илларионов А. М. Катамнез больных, перенесших инсульт в пожилом и старческом возрасте. Журн невр и психиатр 1967:9.

2. Лишманов Ю. Б., Чернов В. И. Радионуклидная диагностика для практических врачей// Издательство STT, Томск 2004 — 388 с.

3. Мурзалиев А. М., Кадырова З. А., Тургунбаев Д. Д. и др. Профилактика нарушений мозгового кровообращения. ЦАМЖ 1998; 4 (2−3): 111−113.

4. Рябова В. С. Инсульт и его последствия: Автореф. дис… канд. мед. наук: М., 1985;20 с.

5. Сергиенко В. Б., Аншелес А. А. Молекулярные изображения в оценке атеросклероза и перфузии миокарда//Кардиологический вестник 2010; 2: 76−83.

6. Aloya R, Shirvan A, Grimberg H, et al. Molecular imaging of cell death in vivo by a novel small molecule probe// Apoptosis 2006; 11: 2089;2101.

7. American Heart Association, 1997, Heart and Stroke statistics: 1997 Statistical Supplement, Dallas, Tex: American Heart Association.

8. Ballantyne C, Hoogeveen R, Bang H, et al. Lipoprotein-associated phospholipase A2, high-sensitivity C-reactive protein, and risk for incident coronary heart disease in middle-aged men and women in the Atherosclerosis Risk in Communities (ARIC) Study. Circulation 2004;109:837−42.

9. Beanlands RS, Hendry PJ, Masters RG, et al. Delay in revascularization is associated with increased mortality rate in patients with severe left ventricular dysfunction and viable myocardium on fluorine 18-fluorodeoxyglucose positron emission tomography imaging// Circulation 1998; 98: II51- II56.

10. Boekboldt SM, Keller TT, Warebam NJ et al. Serum levels of type II secretory phospholipase A2 and the risk of future coronary artery disease in apparently healthy men and women: the EPIC-Norfolk Prosprctive Population Study. Arterioscler Tromb Vasc Biol 2005;25(4):839−43.

11. Cai H, Harrison DG. Endothelial dysfunction in cardiovascular diseases: the role of oxidant stress// Circ Res 2000; 87: 840−844.

12. Caslake MJ, Packard CJ. Lipoprotein-associated phospholipase A2 as a biomarker for coronary disease and stroke. Nat Clin Pract Cardiovasc Med 2005;2 (10): 529−35.

13. Choi Y, Brunken RC, Hawkins RA, et al. Factors affecting myocardial 2-[F-18]fluoro-2-deoxy-D-glucose uptake in positronemission tomography studies of normal humans// Eur J Nucl Med 1993; 20: 308−318.

14. Cojocaru IM, Cojocaru M, Tгnгsescu R et al. Phospholipase A2 in patients with noncardioembolic ischemic stroke and severe inflammatory reaction. Rom J Intern Med 2009;47(1):61−5.

15. Corson MA et al. Review of the evidence for the clinical utility of lipoprotein-associated phospholipase A2 as a cardiovascular risk marker. Am J Cardiol 2008 ;101(12A):41F-50 °F.

16. Cucchiara BL, Messe SR, Sansing L et al. Lipoprotein-associated phospholipase A2 and C-reactive protein for risk-stratification of patients with TIA. Stroke 2009;40(7):2332−6.

17. Danial NN, Korsmeyer SJ. Cell death: critical control points// Cell 2004; 116: 205−219.

18. Elkind MS, Tai W, Coates K et al. High-sensitivity C-reactive protein, lipoprotein-associated phospholipase A2, and outcome after ischemic stroke. Arch Intern Med 2006;166(19):2073;80.

19. Elkind MS, Tai W, Coates K et al. Lipoprotein-associated phospholipase A2 activity and risk of recurrent stroke. Cerebrovasc Dis 2009;27(1):42−50.

20. ESH-ESC Guidelines Committee. 2007 guidelines for the management of arterial hypertension. J Hypertension 2007; 25: 1105−87.

21. Frangioni J.V., Hajjar R.J. In vivo tracking of stem cells for clinical trials in cardiovascular disease// Circulation 2004;110:3378−3384.

22. Garza CA, Montori VM, McConnell JP. Association between Lipoprotein-associated Phospholipase A2 and Cardiovascular Disease: A Systematic Rewiew: Mayo Clin Proc/ 2007; 82(2): 159−165.

23. Gorelick PB. Lipoprotein-associated phospholipase A2 and risk of stroke. Am J Cardiol 2008;101(12A):34F-40 °F.

24. Heart Protection Study Collaborative Group. Lipoprotein-associated phospholipase A2 activity and mass in relation to vascular disease and nonvascular mortality. J Intern Med. 2010;268(4):348−58.

25. Jenny NS, Solomon C, Cushman M et al. Lipoprotein-associated phospholipase A (2) (Lp-PLA (2)) and risk of cardiovascular disease in older adults: results from the Cardiovascular Health Study Atherosclerosis. 2010;209(2):528−32.

26. Keng FY Clinical applications of positron emission tomography in cardiology: a review// Аnn Acad Med Singapore 2004; 33: 175−182.

27. Kiechl S, Willeit J, Mayr M et al. Oxidized phospholipids, lipoprotein (a), lipoprotein-associated phospholipase A2 activity, and 10-year cardiovascular outcomes: prospective results from the Bruneck study. Arterioscler Thromb Vasc Biol. 2007;27(8):1788−95.

28. Kitsiou AN, Bacharach SL, Bartlett ML, et al. 13N-ammonia myocardial blood flow and uptake: relation to functional outcome of asynergic regions after revascularization// J Am Coll Cardiol 1999; 33: 678−686.

29. Knuuti J, Takala TO, Nagren K, et al. Myocardial fatty acid oxidation in patients with impaired glucose tolerance// Diabetologia 2001; 44: 84−187.

30. Korngold EC, Jaffer FA, David RW, Sosnovik E. Noninvasive imaging of apoptosis in cardiovascular disease// Heart Fail Rev 2008; 13: 163−173.

31. Leonberg SC Jr, Elliott FA: Prevention of recurrent stroke. Stroke 1981;12:731−735.

32. Lerman A et al. Lipoprotein-associated phospholipase A2: a risk marker or a risk factor? Am Cardiol. 2008; 101(12A):11F-22 °F.

33. MсMacphee CH. Lipoprotein-associated phospholipase A2: a potential new risk factor for coronary artery disease and a therapeutic target. Curr Opin Pharmacol 2001;1:121−5. 27.

34. Nambi V, Hoogeveen RC, Chambless L et al. Lipoprotein-associated phospholipase A2 and high-sensitivity C-reactive protein improve the stratification of ischemic stroke risk in the Atherosclerosis Risk in Communities (ARIC) study. Stroke. 2009;40(2):376−81.

35. Oei HH, Van der Meer IM, Hofman A, et al. Lipoprotein-associated phospholipase A2 activity is associated with risk of coronary heart disease and ischemic stroke: the Rotterdam study. Circulation 2005;111:570−75.

36. Persson M, Berglund G, Nelson JJ, Hedblad B. Lp-PLA2 activity and mass are associated with increased incidence of ischemic stroke: a population-based cohort study from Malmц, Sweden. Atherosclerosis. 2008;200(1):191−8.

37. Persson M, Hedblad B, Nelson JJ, Berglund G. Elevated Lp-PLA2 levels add prognostic information to the metabolic syndrome on incidence of cardiovascular events among middle-aged nondiabetic subjects Arterioscler Thromb Vasc Biol. 2007;27(6):1411−6.

38. Persson M, Nilsson JA, Hedblad B et al. Lipoproteinassociated phospholipase A2 predicts cardiovascular events. Presented at: Scientific Sessions 2005 of the American Heart Association; Dallas, Tex; November 13−16, 2005.

39. Peterson LR, Herrero P, Schechtman KB, et al. Effect of obesity and insulin resistance on myocardial substrate metabolism and efficiency in young women// Circulation 2004; 109: 2191−2196.

40. PROGRESS Collaborative Group. Randomized trial of a perindopril-based blood-pressure — lowering regimen among 6105 individuals with previous stroke or transient ischemic attack. Lancet 2001;358:1033−1041.

41. Rothwell PM, Coull AJ, Silver LE. et al. Population-based study of event-rate, incidence, case fatality, and mortality for all acute vascular events in all arterial territories (Oxford Vascular Study). Lancet. 2005;366(9499):1773−83.

42. Rudd J.H.F., Warburton E.A., Fryer T. D et al. Imaging Atherosclerotic Plaque Inflammation With [18F]-Fluorodeoxyglucose Positron Emission Tomography// Circulation 2002; 105: 2708−2711.

43. Sabatine MS, Morrow DA, O’Donoghue M et al. PEACE Investigators. Prognostic utility of lipoprotein-associated phospholipase A2 for cardiovascular outcomes in patients with stable coronary artery disease. Arterioscler Thromb Vasc Biol. 2007;27(11):2463−9.

44. Sacco RL, Wolf PA, Kannel WB, McNamara PM. 1982. Survival and recurrence following stroke. The Framingham study. Stroke 13:290−295.

45. Szczepaniak LS, Dobbins RL, Metzger GJ, et al. Myocardial triglycerides and systolic function in humans: in vivo evaluation by localized proton spectroscopy and cardiac imaging// Magn Reson Med 2003; 49: 417−423.

46. van Oijen M, van der Meer IM, Hofman A et al. Lipoprotein-associated phospholipase A2 is associated with risk of dementia. Ann Neurol. 2006;59(1):139−44.

47. Wassertheil-Smoller S, Kooperberg C, McGinn AP et al. Lipoprotein-associated phospholipase A2, hormone use, and the risk of ischemic stroke in postmenopausal women Hypertension. 2008;51(4):1115−22.

48. Wright CB, Moon Y, Paik MC et al. Inflammatory biomarkers of vascular risk as correlates of leukoariosis. Stroke. 2009;40(11):3466−71.

49. Lavi S, McConnell JP, Rihal CS et al. Local production of lipoprotein-associated phospholipase A2 and lysophosphatidylcholine in the coronary circulation: association with early coronary atherosclerosis and endothelial dysfunction in humans. Circulation. 2007;115(21):2715−21.